ornithylaspartate has been researched along with ammonium hydroxide in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 10 (18.52) | 18.2507 |
| 2000's | 11 (20.37) | 29.6817 |
| 2010's | 29 (53.70) | 24.3611 |
| 2020's | 3 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Bueverov, AO; Nadinskaia, MIu; Podymova, SD | 1 |
| Held, C; Kircheis, G; Krüger, B | 1 |
| Gladisch, R; Hagmüller, E; Holm, E; Kortsik, C; Leweling, H; Staedt, U | 1 |
| Eisenburg, J | 1 |
| Boveé, WM; Chamuleau, RA; Karlsen, OT; Mass, MA; Vogels, BA | 1 |
| Berndt, H; Buchner, M; Görtelmeyer, R; Held, C; Hendricks, R; Kircheis, G; Krüger, B; Kuklinski, B; Meister, H; Nilius, R; Otto, HJ; Rink, C; Rösch, W; Stauch, S | 1 |
| Beckers, G; Gaunitz, F; Gebhardt, R; Haupt, W; Jonitza, D; Klein, S; Scheja, L | 1 |
| Adler, G; Beckh, K; Ditschuneit, H; Görtelmeyer, R; Hendricks, R; Heuser, A; Karoff, C; Kircheis, G; Malfertheiner, P; Mayer, D; Rösch, W; Stauch, S; Steffens, J | 1 |
| Butterworth, RF; Kircheis, G; Michalak, A; Pannunzio, P; Quack, G; Rose, C; Therrien, G | 1 |
| Butterworth, RF; Kircheis, G; Michalak, A; Quack, G; Rao, KV; Rose, C | 1 |
| Al Mardini, H; Hudson, M; Oppong, K; Record, CO; Rees, CJ | 1 |
| Dahl, Sv; Häussinger, D; Kircheis, G; Wettstein, M | 1 |
| CIMINO, F; CITTADINI, D; DAYELLO CARACCIOLO, M; SALVATORE, F | 1 |
| Häussinger, D; Wettstein, M | 1 |
| Butterworth, RF | 2 |
| Bautista, JD; Grande, L; Ramos Guerrero, RM; Romero Gómez, M; Sánchez Muñoz, D | 1 |
| Gregor, M; Hass, HG; Hösl, F; Kaiser, S; Nägele, T; Seeger, U | 1 |
| Iberer, F; Portugaller, HR; Stadlbauer, V; Stauber, RE; Stiegler, P; Tauss, J | 1 |
| Ahmad, I; Alam, A; Butt, AK; Dilshad, A; Khan, AA; Malik, K; Sarwar, S; Shafqat, F | 1 |
| Ferenci, P; Gangl, A; König, F; Mittermaier, C; Peck-Radosavljevic, M; Schmid, M | 1 |
| Ameri, AA | 1 |
| Jalan, R; Noiret, L; Olde Damink, SW; Wright, G | 1 |
| Ndraha, S; Simadibrata, M | 1 |
| Hasan, I; Ndraha, S; Simadibrata, M | 1 |
| Mittal, VV; Sarin, SK; Sharma, BC; Sharma, P | 1 |
| Blanco Vela, CI; Poo Ramírez, JL | 1 |
| Abdo Francis, JM; Higuera de la Tijera, F; Pérez Hernández, JL; Serralde-Zúñiga, AE | 1 |
| Fehérvári, I; Gerlei, Z; Görög, D; Kóbori, L; Nemes, B | 1 |
| Bai, M; Fan, D; Han, G; Qi, X; Yang, Z | 1 |
| Bai, M; Bai, W; Cai, H; Fan, D; Guo, W; Han, G; He, C; Liu, L; Niu, J; Qi, X; Tie, J; Wang, J; Wang, Z; Wu, K; Xia, J; Yang, Z; Yin, Z | 1 |
| Manzhaliĭ, EH; Moĭseienko, VO; Nykula, TD; Solonovych, OS | 1 |
| Braddock, M; Chen, YP; Huang, GQ; Huang, S; Lin, YQ; Shi, KQ; Wang, LR; Zheng, MH; Zhu, GQ | 1 |
| Utzt, MJ | 1 |
| Sussman, NL | 1 |
| Petersen, KU | 1 |
| Ahn, JO; Chung, JY; Han, SM; Hwang, CY; Lee, YH; Li, Q; Youn, HY | 1 |
| Dabrowski, J; Hilgier, W; Krzeminski, K; Mikulski, T; Ziemba, A | 1 |
| Cámara-Lemarroy, CR; Delgado-García, G; Estrada-Bellmann, I; García-Valadez, E; Monreal-Robles, R | 1 |
| Arias, N; Hadjihambi, A; Jalan, R; Sheikh, M | 1 |
| Dahale, AS; Sachdeva, S; Sharma, BC; Srivastava, S; Varakanahalli, S | 1 |
| Cai, XJ; Hu, CM; Wang, L | 1 |
| Canbay, A; Sowa, JP | 1 |
| Kircheis, G; Lüth, S | 1 |
| Butterworth, RF; McPhail, MJW | 1 |
| Alsahhar, JS; Rahimi, RS | 1 |
| Bogomolov, PO; Buyeverov, AO; Matsievich, MV; Mayev, IV; Uvarova, OV | 1 |
| Boutros, S; Saab, S; Winters, A; Yanny, B | 1 |
| Alimirah, M; Gordon, SC; Sadiq, O | 1 |
| Fan, Y; Jiang, H; Li, M; Shao, J; Zhang, M | 1 |
| Fang, Y; Fang, Z; Hui, L; Yu-E, Y; Zheng-Li, D; Zhi-Qin, L | 1 |
19 review(s) available for ornithylaspartate and ammonium hydroxide
| Article | Year |
|---|---|
[Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies].
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Function Tests; Randomized Controlled Trials as Topic; Treatment Outcome | 1994 |
[Hepatic minimal encephalopathy. The most frequently overlooked, clinically occult "metabolic syndrome" on the cirrhosis patient].
Topics: Ammonia; Arginine; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Neuropsychological Tests; Prognosis; Psychometrics | 1996 |
Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Muscular Diseases; Severity of Illness Index | 2002 |
[Hepatic encephalopathy--therapy].
Topics: Administration, Oral; Ammonia; Anti-Bacterial Agents; Diet, Protein-Restricted; Dipeptides; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Humans; Liver Diseases | 2003 |
Brain edema in acute liver failure.
Topics: Ammonia; Animals; Astrocytes; Brain Edema; Dipeptides; Humans; Hypothermia, Induced; Intracranial Pressure; Liver Failure, Acute | 2003 |
[New concepts in the physiopathology of hepatic encephalopathy and therapeutic prospects].
Topics: Ammonia; Brain; Brain Edema; Dipeptides; Flumazenil; Glutaminase; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Inflammation; Intestine, Small; Kidney; Memantine; Models, Molecular; Nerve Tissue Proteins; Nitric Oxide | 2004 |
Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.
Topics: Adipose Tissue; Amino Acids; Ammonia; Arginine; Brain; Dipeptides; Glutamate-Ammonia Ligase; Glutaminase; Hepatic Encephalopathy; Humans; Hyperammonemia; Intestinal Mucosa; Kidney; Liver; Liver Failure; Lung; Muscles; Phenylbutyrates; Sodium Benzoate | 2011 |
Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.
Topics: Adult; Aged; Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Liver Failure; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
[Hepatic encephalopathy and liver transplantation].
Topics: Ammonia; Anti-Infective Agents; Colon; Dipeptides; Disaccharides; End Stage Liver Disease; Evidence-Based Medicine; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hungary; Hydrogen-Ion Concentration; Lactobacillus; Lactulose; Laxatives; Liver Cirrhosis; Liver Transplantation; Metronidazole; Neomycin; Rifamycins; Rifaximin; Severity of Illness Index; Sugar Alcohols; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2012 |
l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
Topics: Amino Acids, Branched-Chain; Ammonia; Dipeptides; Disaccharides; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Mental Health; Neomycin; Randomized Controlled Trials as Topic; Rifamycins; Rifaximin | 2015 |
Treatment of Overt Hepatic Encephalopathy.
Topics: Amino Acids, Branched-Chain; Ammonia; Arteriovenous Fistula; Dipeptides; Gastrointestinal Agents; Glycerol; Hepatic Encephalopathy; Humans; Lactulose; Liver Failure; Malnutrition; Ornithine; Phenylbutyrates; Probiotics; Rifamycins; Rifaximin | 2015 |
Hepatic encephalopathy: a critical current review.
Topics: Albumins; Ammonia; Anti-Bacterial Agents; Bile Acids and Salts; Brain; Brain Edema; Cognitive Dysfunction; Dipeptides; Energy Metabolism; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Ornithine; Portasystemic Shunt, Surgical; Prognosis; Psychometrics; Severity of Illness Index; Synaptic Transmission | 2018 |
Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Topics: Ammonia; Animals; Brain; Dipeptides; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Muscles; Rats; Signal Transduction | 2019 |
L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Secondary Prevention; Systematic Reviews as Topic; Treatment Outcome | 2019 |
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Topics: Amino Acids, Aromatic; Amino Acids, Branched-Chain; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Frailty; Gastrointestinal Agents; Gastrointestinal Microbiome; Glycerol; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Ornithine; Phenylbutyrates; Polyethylene Glycols; Probiotics; Rifaximin; Trace Elements; Zinc | 2019 |
L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Topics: Ammonia; Dipeptides; End Stage Liver Disease; Humans; Hyperammonemia; Liver; Sarcopenia; Treatment Outcome | 2019 |
Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach.
Topics: Amino Acids, Branched-Chain; Ammonia; Caregivers; Cost of Illness; Dipeptides; Embolization, Therapeutic; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Neomycin; Patient Readmission; Rifaximin; Severity of Illness Index; Sodium Benzoate; Sorption Detoxification; Zinc | 2019 |
Novel Therapies in Hepatic Encephalopathy.
Topics: Acetylcarnitine; Albumins; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Flumazenil; GABA Modulators; Glycerol; Hepatic Encephalopathy; Humans; Nootropic Agents; Ornithine; Phenylbutyrates; Polyethylene Glycols; Probiotics; Surface-Active Agents | 2020 |
12 trial(s) available for ornithylaspartate and ammonium hydroxide
| Article | Year |
|---|---|
[The treatment of hepatic encephalopathy with Hepa-Mertz].
Topics: Ammonia; Biomarkers; Chronic Disease; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Psychomotor Performance; Time Factors | 1995 |
Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design.
Topics: Adult; Amino Acids; Ammonia; Blood Glucose; Dipeptides; Double-Blind Method; Female; Humans; Insulin; Liver Cirrhosis; Male; Middle Aged; Urea | 1993 |
Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Topics: Adult; Aged; Ammonia; Dipeptides; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Liver Cirrhosis; Male; Mental Health; Middle Aged; Placebos; Veins | 1997 |
Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Topics: Administration, Oral; Adult; Ammonia; Dietary Proteins; Dipeptides; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Placebos; Postprandial Period | 1998 |
Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
Topics: Ammonia; Dipeptides; Double-Blind Method; Electroencephalography; Glutamine; Humans; Liver Cirrhosis, Alcoholic; Middle Aged; Portasystemic Shunt, Transjugular Intrahepatic; Psychometrics | 2000 |
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognition; Dipeptides; Female; Health Status Indicators; Hepatic Encephalopathy; Humans; Hyperammonemia; Infusions, Intravenous; Liver Cirrhosis; Male; Middle Aged; Postprandial Period | 2008 |
A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Topics: Aged; Ammonia; Biopsy, Needle; Dipeptides; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hepatic Encephalopathy; Humans; Immunohistochemistry; Infusions, Intravenous; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pilot Projects; Postural Balance; Psychometrics; Reference Values; Risk Assessment; Sensation Disorders; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2010 |
The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
Topics: Adult; Aged; Albumins; Amino Acids, Branched-Chain; Ammonia; Dietary Proteins; Dipeptides; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male; Malnutrition; Middle Aged; Nutritional Status; Young Adult | 2011 |
A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Topics: Adult; Ammonia; Dipeptides; Female; Hepatic Encephalopathy; Humans; Lactulose; Male; Middle Aged; Neuropsychological Tests; Probiotics; Psychometrics; Quality of Life; Severity of Illness Index; Treatment Outcome | 2011 |
Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
Topics: Adult; Ammonia; Dipeptides; Female; Hepatic Encephalopathy; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Portasystemic Shunt, Transjugular Intrahepatic; Postprandial Period; Psychometrics; Treatment Outcome | 2014 |
Effects of supplementation with branched chain amino acids and ornithine aspartate on plasma ammonia and central fatigue during exercise in healthy men.
Topics: Adult; Amino Acids, Branched-Chain; Ammonia; Cross-Over Studies; Dietary Supplements; Dipeptides; Double-Blind Method; Exercise; Health Status; Humans; Male; Muscle Fatigue; Physical Endurance | 2015 |
Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Topics: Adult; Ammonia; Biomarkers; Chi-Square Distribution; Dipeptides; Double-Blind Method; Female; Flicker Fusion; Hepatic Encephalopathy; Humans; India; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neuropsychological Tests; Odds Ratio; Psychometrics; Recurrence; Risk Factors; Secondary Prevention; Sickness Impact Profile; Tertiary Care Centers; Time Factors; Treatment Outcome | 2018 |
23 other study(ies) available for ornithylaspartate and ammonium hydroxide
| Article | Year |
|---|---|
L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats.
Topics: Ammonia; Analysis of Variance; Animals; Brain; Brain Diseases; Dipeptides; Drug Therapy, Combination; Magnetic Resonance Spectroscopy; Male; Microdialysis; Nitrogen; Ornithine; Portacaval Shunt, Surgical; Protons; Rats; Rats, Wistar; Synaptic Transmission | 1997 |
Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels.
Topics: Amino Acids; Ammonia; Animals; Carbon Tetrachloride; Dipeptides; Liver; Liver Cirrhosis, Experimental; Rats; Urea | 1997 |
L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action.
Topics: Ammonia; Animals; Dipeptides; Glutamic Acid; Hepatic Encephalopathy; Male; Portacaval Shunt, Surgical; Rats; Rats, Sprague-Dawley; Urea | 1998 |
L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
Topics: Ammonia; Animals; Brain Edema; Dipeptides; Glutamic Acid; Liver Failure, Acute; Male; Rats; Rats, Sprague-Dawley | 1999 |
[Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin | 2000 |
MECHANISM OF THE PROTECTION BY L-ORNITHINE-L-ASPARTATE MIXTURE AND BY L-ARGININE IN AMMONIA INTOXICATION.
Topics: Ammonia; Arginine; Aspartic Acid; Chemical and Drug Induced Liver Injury; Dipeptides; Hepatitis; Ligases; Metabolism; Ornithine; Pharmacology; Rats; Research; Toxicology; Urea | 1964 |
[Because hepatic encephalopathy is a frequent contributing factor. Patients with liver cirrhosis are poorer drivers].
Topics: Accidents, Traffic; Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Cirrhosis | 2003 |
[Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Quality of Life; Self-Help Groups | 2004 |
[Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Topics: Adult; Ammonia; Brain; Choline; Combined Modality Therapy; Creatinine; Diet, Protein-Restricted; Dipeptides; Energy Metabolism; Female; Follow-Up Studies; Glutamic Acid; Glutamine; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Inositol; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Prospective Studies; Reference Values; Statistics as Topic | 2005 |
Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.
Topics: Aged; Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Liver Diseases, Alcoholic; Liver Transplantation; Male; Portasystemic Shunt, Transjugular Intrahepatic; Postoperative Complications; Stents | 2007 |
[Hepatic encephalopathy. L-ornithine-L-aspartate stimulate detoxification capacity of the liver].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Humans; Liver; Liver Function Tests; Neuropsychological Tests | 2010 |
Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
Topics: Ammonia; Dietary Proteins; Dipeptides; Dose-Response Relationship, Drug; Follow-Up Studies; Hepatic Encephalopathy; Humans; Male; Middle Aged | 2010 |
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Topics: Administration, Oral; Ammonia; Dipeptides; Glutamine; Hepatic Encephalopathy; Humans; Hyperammonemia; Liver Cirrhosis; Quality of Life; Severity of Illness Index; Treatment Outcome; Urea | 2011 |
[Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis].
Topics: Adult; Aged; Ammonia; Citric Acid Cycle; Dipeptides; Event-Related Potentials, P300; Female; Hepatic Encephalopathy; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Protective Agents; Severity of Illness Index | 2014 |
[In Process Citation].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Early Diagnosis; Early Medical Intervention; Evidence-Based Medicine; Hepatic Encephalopathy; Humans; Lactulose; Prognosis; Rifamycins; Rifaximin | 2015 |
[Options in the treatment of hepatic encephalopathy].
Topics: Amino Acids, Branched-Chain; Ammonia; Anti-Bacterial Agents; Dipeptides; Hepatic Encephalopathy; Humans; Rifamycins; Rifaximin | 2015 |
Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
Topics: Ammonia; Animals; Dipeptides; Dog Diseases; Dogs; Female; Hepatic Encephalopathy; Hyperammonemia; Male | 2016 |
Anti-ammonia treatment-responsive myoclonus as initial presentation of acquired hepatocerebral degeneration.
Topics: Ammonia; Dipeptides; Female; Hepatolenticular Degeneration; Humans; Lactulose; Middle Aged; Myoclonus | 2018 |
Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Topics: Acetylcarnitine; Adult; Ammonia; Dipeptides; Female; Hepatic Encephalopathy; Humans; Lactulose; Male; Middle Aged; Network Meta-Analysis; Neuroprotective Agents; Probiotics; Randomized Controlled Trials as Topic; Rifaximin; Serum Albumin; Treatment Outcome | 2018 |
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Topics: Ammonia; Animals; Antioxidants; Dipeptides; Fatty Liver; Glutamine; Glutathione; Humans; Liver; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2019 |
Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Topics: Adult; Ammonia; Case-Control Studies; Dipeptides; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Hyperammonemia; Male; Treatment Outcome | 2019 |
Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate.
Topics: Ammonia; Animals; Catfishes; Dipeptides; Hyperammonemia; Sodium Chloride | 2022 |
Valproate-induced hyperammonemic encephalopathy treated by L-ornithine-L-aspartate: a case report.
Topics: Ammonia; Anticonvulsants; Brain Diseases; Humans; Male; Middle Aged; Valproic Acid | 2023 |